United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
United Therapeutics received FDA premarket approval for the LungFX device, the first device cleared for centralized ex vivo lung perfusion to assess donor organs outside the body. The company intends to add LungFX to its subsidiary Lung Bioengineering's service offerings in 2027, aiming to increase the utilization of donor lungs that are currently discarded.
Key figures
- Drug Name
- LungFX
- Evlp procedures to date
- 1100
- Expected service launch year
- 2027
- Lungs accepted for transplant
- 600
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.